SGMO – Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

SGMO

$0.53

Name : Sangamo Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $130,063,056.00

EPSttm : -0.36

Sangamo Therapeutics, Inc.

$0.53

7.72%

$0.038

Float Short %

13.43

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.02

EPS Last/This Y

0.03

EPS This/Next Y

0.05

Price

0.53

Target Price

4.1

Analyst Recom

1.71

Performance Q

-49.04

Relative Volume

0.91

Beta

1.21

Ticker: SGMO

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	SGMO	0.7197	0.51	0.12	94197
2025-05-09	SGMO	0.7003	0.50	0.00	95066
2025-05-12	SGMO	0.7509	0.49	0.07	95967
2025-05-13	SGMO	0.4621	0.49	0.17	96813
2025-05-14	SGMO	0.438	0.37	0.12	94880
2025-05-15	SGMO	0.4513	0.33	0.29	92932
2025-05-16	SGMO	0.4727	0.33	0.03	93388
2025-05-19	SGMO	0.4952	0.44	0.04	55945
2025-05-20	SGMO	0.5	0.42	0.03	57582
2025-05-21	SGMO	0.5034	0.42	0.00	57942
2025-05-22	SGMO	0.494	0.41	0.00	59067
2025-05-23	SGMO	0.4737	0.40	0.00	60225
2025-05-27	SGMO	0.4501	0.38	0.00	62624
2025-05-28	SGMO	0.4461	0.34	0.01	66798
2025-05-29	SGMO	0.4559	0.31	0.01	71766
2025-05-30	SGMO	0.465	0.31	0.00	72545
2025-06-02	SGMO	0.4673	0.31	0.00	72908
2025-06-03	SGMO	0.4999	0.30	0.02	73640
2025-06-04	SGMO	0.496	0.30	0.00	74543
2025-06-05	SGMO	0.4949	0.29	0.00	75614
2025-06-06	SGMO	0.53	0.29	0.25	76490
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	SGMO	0.72	47.6	-	-0.34
2025-05-09	SGMO	0.70	47.6	-	-0.34
2025-05-12	SGMO	0.75	47.6	-	-0.34
2025-05-13	SGMO	0.46	47.6	-	-0.34
2025-05-14	SGMO	0.44	47.6	-	-0.34
2025-05-15	SGMO	0.45	47.6	-	-0.34
2025-05-16	SGMO	0.47	47.6	-	-0.34
2025-05-19	SGMO	0.50	41.7	-	-0.46
2025-05-20	SGMO	0.50	41.7	-	-0.46
2025-05-21	SGMO	0.50	41.7	-	-0.46
2025-05-22	SGMO	0.49	41.7	-	-0.46
2025-05-23	SGMO	0.47	41.7	-	-0.46
2025-05-27	SGMO	0.45	41.7	-	-0.46
2025-05-28	SGMO	0.45	41.7	-	-0.46
2025-05-29	SGMO	0.46	41.7	-	-0.46
2025-05-30	SGMO	0.47	41.7	-	-0.46
2025-06-02	SGMO	0.47	41.7	-	-0.46
2025-06-03	SGMO	0.50	41.7	-	-0.46
2025-06-04	SGMO	0.49	41.7	-	-0.46
2025-06-05	SGMO	0.49	41.7	-	-0.46
2025-06-06	SGMO	0.53	41.7	-	-0.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	SGMO	0.00	5.65	13.83
2025-05-09	SGMO	0.00	5.65	13.56
2025-05-12	SGMO	0.00	3.35	12.89
2025-05-13	SGMO	0.00	3.35	12.89
2025-05-14	SGMO	0.00	3.35	12.89
2025-05-15	SGMO	0.00	3.35	12.67
2025-05-16	SGMO	0.00	3.35	12.67
2025-05-19	SGMO	0.00	27.08	12.04
2025-05-20	SGMO	0.00	27.08	12.04
2025-05-21	SGMO	0.00	27.08	12.04
2025-05-22	SGMO	0.00	27.08	12.04
2025-05-23	SGMO	0.00	27.08	12.04
2025-05-27	SGMO	0.00	-14.84	12.04
2025-05-28	SGMO	0.00	-14.84	13.60
2025-05-29	SGMO	0.00	-14.84	13.60
2025-05-30	SGMO	0.00	-14.84	13.60
2025-06-02	SGMO	0.00	-14.84	13.62
2025-06-03	SGMO	0.00	-14.84	13.43
2025-06-04	SGMO	0.00	-14.84	13.43
2025-06-05	SGMO	0.00	-14.84	13.43
2025-06-06	SGMO	0.00	-14.84	13.43
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.14

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-14.84

Beta

1.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-98.4

Target Price

4.1

P/E

Forward P/E

PEG

P/S

2.04

P/B

24.35

P/Free Cash Flow

EPS

-0.38

Average EPS Est. Cur. Y

-0.46

EPS Next Y. (Est.)

-0.4

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-126.63

Relative Volume

0.91

Return on Equity vs Sector %

-1643.5

Return on Equity vs Industry %

-1625.5

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.12

EBIT Estimation

Sangamo Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 183

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

stock quote shares SGMO – Sangamo Therapeutics, Inc. Stock Price stock today

news today SGMO – Sangamo Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SGMO – Sangamo Therapeutics, Inc. yahoo finance google finance

stock history SGMO – Sangamo Therapeutics, Inc. invest stock market

stock prices SGMO premarket after hours

ticker SGMO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

SGMO – Sangamo Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SGMO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y